SynthesisDrugs & aging2017
Effectiveness of Interventions to Deprescribe Inappropriate Proton Pump Inhibitors in Older Adults.
Synthesis in Drugs & aging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06858384 (From Awareness to Action), which is not on this map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
From Awareness to Action: Transforming Proton Pump Inhibitor Use in Ras Al Khaimah Through Education and Intervention: the RAK -PRIDE Study
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Deprescribing Interventions among Community-Dwelling Older Adults: A Systematic Review of Economic Evaluations.PharmacoEconomics · 2022Pooled it
- Evidence for deprescription in primary care through an umbrella review.BMC family practice · 2020Pooled it
- Pooled it
- Efficacy of a computer based discontinuation strategy to reduce PPI prescriptions: a multicenter cluster-randomized controlled trial.Scientific reports · 2023Trial
- Prescriber Implementation of STOPP/START Recommendations for Hospitalised Older Adults: A Comparison of a Pharmacist Approach and a Physician Approach.Drugs & aging · 2019Trial
- Deprescribing proton pump inhibitors in long-term care: Outcomes of a pharmacist-led initiative.Exploratory research in clinical and social pharmacy · 2026Article
- Appropriate prescribing and deprescribing of proton pump inhibitors: New Choosing Wisely Canada toolkit.Canadian family physician Medecin de famille canadien · 2026Article
- Burden and Determinants of Drug-Drug Interactions at Hospital Discharge: Warfarin as a Model for High-Risk Medication Safety.Clinics and practice · 2025Article
- Development of a Deprescribing Intervention for Proton Pump Inhibitors in Primary Care: A Co-Design Approach With General Practitioners and Patients.Basic & clinical pharmacology & toxicology · 2025Article
- Article
- Determinants of and interventions for Proton Pump Inhibitor prescription behavior: A systematic scoping review.BMC primary care · 2024Article
- Impact of large scale, multicomponent intervention to reduce proton pump inhibitor overuse in integrated healthcare system: difference-in-difference study.BMJ (Clinical research ed.) · 2024Article
- Article
- Improving the feasibility of deprescribing proton pump inhibitors: GPs' insights on barriers, facilitators, and strategies.Frontiers in pharmacology · 2024Article
- Ceftriaxone and the Risk of Ventricular Arrhythmia, Cardiac Arrest, and Death Among Patients Receiving Lansoprazole.JAMA network open · 2023Article
- Inappropriate proton pump inhibitor lansoprazole prescription in older adults hospitalized in long-term care unit.Irish journal of medical science · 2023Article
- Analysis of deprescription strategies of proton pump inhibitors in primary care: a narrative review.Primary health care research & development · 2023Review
- Prescribing trends of proton pump inhibitors, antipsychotics and benzodiazepines of medicare part d providers.BMC geriatrics · 2022Article
- Effectiveness of a multi-faceted intervention to deprescribe proton pump inhibitors in primary care: protocol for a population-based, pragmatic, cluster-randomized controlled trial.BMC health services research · 2022Article
- Using electronic admission data to monitor temporal trends in local medication use: Experience from an Australian tertiary teaching hospital.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of proton pump inhibitors (PPIs) in older adults is high, often inappropriate, and may cause harm. Deprescribing is defined as the reduction, withdrawal, or discontinuation of inappropriate medication.
objectiveWe conducted a systematic review to determine the effectiveness of interventions to deprescribe inappropriate PPIs in older adults.
methodsWe searched MEDLINE, PubMed, Embase, the Cochrane Library, ProQuest Dissertations and Theses Global, and Google from inception to January 2017 for randomized and non-randomized studies describing the outcomes of interventions to deprescribe inappropriate PPIs in older adults (mean or median age of ≥65 years). Where available, clinically relevant outcomes were also assessed.
resultsWe included 21 articles in our review. Six studies demonstrated effective interventions, 11 were inconclusive, and four were ineffective. Effective interventions included a population-wide education and promotion strategy, academic detailing for general practitioners, and inpatient geriatrician-led deprescribing. Methodological issues limited the interpretation of several studies. Standardization in outcome reporting was lacking, and clinical outcome data were absent. A comparison of intervention effectiveness was not possible because of their heterogeneity, which precluded a meta-analysis.
conclusionThe limited available evidence suggests that some strategies are more successful than others in effectively deprescribing inappropriate PPIs in older adults. However, whether PPI deprescribing translates into better clinical outcomes remains unclear.
Indexed as
Identifiers
28220380What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.